NATIONAL INSTITUTES OF HEALTH
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 2
Completed
- Conditions
- Angioimmunoblastic T-cell LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell LymphomaRecurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Diffuse Mixed Cell LymphomaRecurrent Adult Diffuse Small Cleaved Cell LymphomaRecurrent Adult Immunoblastic Large Cell LymphomaRecurrent Adult Lymphoblastic LymphomaRecurrent Adult T-cell Leukemia/Lymphoma
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 72
- Registration Number
- NCT00006473
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous Leukemia
Phase 2
Terminated
- Conditions
- Blastic Phase Chronic Myelogenous LeukemiaChronic Myelogenous Leukemia, BCR-ABL1 Positive
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT00023920
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Interleukin-12 in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Phase 2
Completed
- Conditions
- Primary Peritoneal Cavity CancerRecurrent Ovarian Epithelial Cancer
- Interventions
- Biological: recombinant interleukin-12
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00016289
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Decitabine in Treating Children With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
Phase 1
Terminated
- Conditions
- Childhood Acute Myeloblastic Leukemia With Maturation (M2)Childhood Acute Promyelocytic Leukemia (M3)Recurrent Childhood Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Myeloid LeukemiaSecondary Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 21
- Registration Number
- NCT00042796
- Locations
- 🇺🇸
Children's Oncology Group, Arcadia, California, United States
506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma
Phase 2
Terminated
- Conditions
- Recurrent Cutaneous T-cell Non-Hodgkin LymphomaRecurrent Mycosis Fungoides/Sezary Syndrome
- Interventions
- Other: pharmacological study
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT00005982
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Imatinib Mesylate in Treating Patients With Stage IV Colorectal Cancer
Phase 2
Completed
- Conditions
- Recurrent Colon CancerRecurrent Rectal CancerStage IV Colon CancerStage IV Rectal Cancer
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 37
- Registration Number
- NCT00041340
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction
Phase 1
Completed
- Conditions
- Adult Primary Hepatocellular CarcinomaAdvanced Adult Primary Liver CancerLocalized Unresectable Adult Primary Liver CancerRecurrent Adult Primary Liver Cancer
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT00047346
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Gefitinib in Treating Children With Refractory Solid Tumors
Phase 1
Completed
- Conditions
- Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 45
- Registration Number
- NCT00040781
- Locations
- 🇺🇸
Children's Oncology Group, Arcadia, California, United States
Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
Phase 2
Completed
- Conditions
- Childhood Chronic Myelogenous LeukemiaChronic Myelogenous Leukemia, BCR-ABL1 PositiveChronic Phase Chronic Myelogenous LeukemiaRelapsing Chronic Myelogenous Leukemia
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT00006364
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
PS-341 in Treating Women With Metastatic Breast Cancer
Phase 2
Completed
- Conditions
- Recurrent Breast CancerStage IV Breast Cancer
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT00025584
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath